Semax vs Selank
How they differ
- FDA status, the same for both (Not FDA-approved). Semax: Not an FDA-approved drug.1 Selank: No FDA approval reported; FDA lists safety concerns from a withdrawn compounding nomination.2
- HHS compounding policy of October 30, 2026. Semax is one of the six peptides the policy lists; Selank is not.3
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | Semax | Selank |
|---|---|---|
| What it is | A synthetic peptide of seven amino acids, designed from a fragment of adrenocorticotropic hormone (ACTH) without that hormone’s hormonal effects.1 | A synthetic heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, according to FDA’s substance registry.4 |
| FDA status | Not FDA-approved Not an FDA-approved drug1 Not FDA-approved. FDA staff recommended in May 2026 against adding Semax to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, Semax free base is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.1,3,5 | Not FDA-approved No FDA approval reported; FDA lists safety concerns from a withdrawn compounding nomination2 No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page lists selank acetate among withdrawn nominations with possible safety risks.2 |
| HHS compounding policy, October 30, 2026 | In the policy: one of the six peptides it lists.3 | Not among the six peptides the policy lists.3 HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Selank is not among them.3,5 |
| FDA compounding safety-risk page | Listed. FDA’s compounding safety-risk page, last updated April 22, 2026, lists Semax among substances whose nominations were withdrawn and says FDA lacks enough information to know whether it would cause harm in people.2 | Listed. FDA’s compounding safety-risk page, current as of April 22, 2026, lists selank acetate among bulk drug substances that were in category 2 before their nominations were withdrawn, citing possible immune reactions from aggregation and impurities.2 |
| Kinds of studies cited |
|
|
| Records collected | 0 ClinicalTrials.gov records and 40 PubMed records collected | 0 ClinicalTrials.gov records and 13 PubMed records collected |
| Area of study | ||
| Latest dated events |
|
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1FDA briefing document for Semax ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 2Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 3HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 4Selank substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 5Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 6Optimization of the treatment of anxiety disorders with selank (2015, in Russian) · PMID 26356395 ↗
Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · Official source · Source checked November 16, 2026
- 7Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats (2017) · PMID 28280289 ↗
Behavioural Neurology · Official source · Source checked November 15, 2026
- 8July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026